SINT

Business Context and Reporting Period

Company: Amedica Corporation (trading as Sintx Technologies, Inc. in metadata, but identified as Amedica Corporation in the filing text).
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2013
Business Overview: A commercial biomaterial company focused on silicon nitride technology for medical devices. The company markets spinal fusion products (Valeo devices) and is developing components for total hip and knee replacements. It operates a vertically integrated manufacturing facility in Salt Lake City, Utah.

Key Financial Metrics

Note: The 2012 net loss included a one-time $15.3 million impairment charge on intangible assets related to the US Spine acquisition, which did not recur in 2013.

Material Changes vs. Prior Period

• Revenue Decline: Total product revenue decreased 3% to $22.3 million. This was driven by an 11% decline in non-silicon nitride product sales, partially offset by a 17% increase in silicon nitride product sales.
• Geographic Shift: International revenue plummeted 91% to $0.1 million due to the absence of a one-time international sale recorded in 2012. Domestic revenue increased 2%.
• Margin Compression: Gross margin decreased from 72% to 68%, primarily due to the implementation of the 2.3% U.S. medical device excise tax in 2013 and increased inventory write-downs for first-generation products.
• Expense Reduction: Operating expenses decreased 44% to $25.6 million, largely due to the absence of the 2012 impairment charge and a 42% reduction in R&D expenses (partially due to reclassifying overhead to inventory).
• Other Income: Other income turned positive at $2.0 million in 2013 (vs. $(6.7) million expense in 2012), driven by a $4.7 million decrease in the fair value of warrant liabilities and reduced interest expense following debt conversions.

Guidance, Outlook, Risks, and Contingencies

Going Concern Warning

The independent auditors have included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern. The company has recurring losses and requires additional financing to satisfy debt obligations and maintain compliance with covenants through 2014.

Liquidity and Debt Covenants

• Debt Structure: The company has an $18.0 million term loan and a $3.5 million revolving credit facility with GE Capital and Zions First National Bank.
• Covenant Default: The company was in default of its liquidity covenant in November 2013. It obtained waivers through February 2014 but anticipates non-compliance prior to December 31, 2014. Consequently, the entire debt obligation is classified as a current liability.
• Financing Needs: The company expects to need additional funding in the third quarter of 2014 to repay $7.2 million in principal due in 2014 and to maintain covenant compliance.

Outlook and Strategy

• Product Launches: Full launch of second-generation Valeo spinal fusion devices expected in Q2 2014. Second-generation Cervical and TL devices expected in H2 2014.
• Clinical Trials: The CASCADE clinical trial in Europe (comparing composite silicon nitride to PEEK) is 100% enrolled, with results expected in H2 2014 to support a U.S. 510(k) submission by mid-2015.
• Joint Replacements: Developing silicon nitride-coated components for hip and knee replacements; FDA pre-submission meeting held in Dec 2013. Commercial launch targeted for H2 2015 if cleared.

Key Risks

• Market Acceptance: Limited market acceptance of silicon nitride products to date; revenue is still predominantly derived from non-silicon nitride products.
• Customer Concentration: One customer (Bon Secours St. Mary's Hospital) accounted for 14% of revenue in both 2012 and 2013.
• Regulatory: Risks associated with FDA clearance for new products and compliance with healthcare fraud and abuse laws (Anti-Kickback Statute).

Investor Verification Checklist

• Capital Raise Status: Verify the status of the Initial Public Offering (IPO) completed in February 2014 (net proceeds ~$15.4 million) and whether it was sufficient to cover the $7.2 million debt principal due in 2014.
• Covenant Compliance: Confirm current compliance with the GE Capital liquidity covenants and the status of any further waivers or refinancing efforts.
• Product Mix: Monitor the ratio of silicon nitride revenue vs. non-silicon nitride revenue to assess the success of the core technology transition.
• Clinical Data: Review the results of the CASCADE clinical trial (expected H2 2014) as a critical milestone for U.S. market expansion of composite devices.
• Customer Concentration: Assess the risk of revenue volatility given the 14% reliance on a single hospital system.